


**Product Name** : PD180970  
**Cat. No.** : PC-73114  
**CAS No.** : 287204-45-9  
**Molecular Formula** : C<sub>21</sub>H<sub>15</sub>Cl<sub>2</sub>FN<sub>4</sub>O  
**Molecular Weight** : 429.27  
**Target** : Bcr-Abl  
**Solubility** : 10 mM in DMSO



## Biological Activity

PD180970 (PD 180970) is an ATP-competitive inhibitor of **p210 bcr/abl** tyrosine kinase, inhibits autophosphorylation of p210Bcr-Abl with IC<sub>50</sub> of 5 nM.

PD180970 selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells.

PD180970 inhibits in vivo tyrosine phosphorylation of Gab2, CrkL and p210bcr/abl (IC<sub>50</sub>, 80, 80 and 170 nM respectively).

PD180970 potently inhibits p210bcr/abl autophosphorylation in vitro (IC<sub>50</sub>=5 nM).

PD180970 also potently inhibits c-Src and KIT (IC<sub>50</sub>, 0.8 and 50 nM, respectively).

PD180970 induces autophagy and reduces neuroinflammation in animal models of Parkinson's disease.

## References

J F Dorsey, et al. *Cancer Res.* 2000 Jun 15;60(12):3127-31.

Paul La Rosée, et al. *Cancer Res.* 2002 Dec 15;62(24):7149-53.

Suresh Sn, et al. *EBioMedicine.* 2019 Dec;50:260-273.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com